PET/CT in the Evaluation of Neuroblastoma

Abstract

I-123-metaiodobenzylguanidine (MIBG) is the most commonly used functional imaging agent in patients with neuroblastoma, but use of [F-18]- FDG PET is increasing. MIBG is useful for defining the extent of disease at diagnosis, following response to treatment, and localizing residual and recurrent disease. In early-stage disease, FDG is often better concentrated in tumor sites than MIBG. In all stages, disease extent in the chest, abdomen, and pelvis and local metastases may be better delineated by FDG. In advanced-stage disease, MIBG is superior for following the treatment response of metastatic tumor in the marrow and bone. Several C-11- and F-18-labeled tracers may be equal to or superior to I-123-MIBG if supply problems can be resolved.

Keywords: FDG; MIBG; Neuroblastoma; PET; PET/CT.